Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexmedetomidine + cisatracurium + sufentanil
- Development stage
- Unknown
- Lead developer
- Orion Pharma
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of three medications used in anesthesia and critical care settings. Dexmedetomidine is a highly selective alpha-2 adrenoreceptor agonist providing sedation and analgesia, sufentanil is a potent opioid analgesic, and cisatracurium is a neuromuscular blocking agent. This combination is used for anesthesia induction, maintenance, and postoperative pain management, offering complementary effects with reduced side effects compared to individual components used alone.
02
Targets
MOR (Mu opioid receptor)Muscle-type nicotinic acetylcholine receptorADRA2A (α2A)
Beyond the preview
Go deeper on dexmedetomidine + cisatracurium + sufentanil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexmedetomidine + cisatracurium + sufentanil.